{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:05:45Z","timestamp":1785855945451,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejim.2023.06.021","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T07:37:11Z","timestamp":1688197031000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2401-3781","authenticated-orcid":false,"given":"Fabricio","family":"Benavides-Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Loricera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Calvo-R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Corrales-Selaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2023.06.021_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.021_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejim.2023.06.021_bib0003","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 american college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejim.2023.06.021_bib0004","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2023.06.021_bib0005","first-page":"168","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"17","author":"Stone","year":"2010","journal-title":"J Fur Miner"},{"key":"10.1016\/j.ejim.2023.06.021_bib0006","first-page":"687","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis rachel","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.06.021_bib0007","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil antibody","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2023.06.021_bib0008","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/rheumatology\/keu429","article-title":"Indications for IVIG in rheumatic diseases","volume":"54","author":"Mulhearn","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2023.06.021_bib0009","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/anr.1780320108","article-title":"Infectious complications complications of cyclophosphamide treatment for vasculitis","volume":"32","author":"Bradley","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.021_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrrheum.2011.61","article-title":"Intravenous immunoglobulin therapy in rheumatic diseases","volume":"7","author":"Bayry","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0011","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1056\/NEJM199107113250207","article-title":"The use of Intravenous Inmune Globulin in Immunodeficiency diseases","volume":"325","author":"Buckley","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.06.021_bib0012","first-page":"81","article-title":"High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood","volume":"36","author":"Imbach","year":"1981","journal-title":"Helv Paediatr Acta"},{"key":"10.1016\/j.ejim.2023.06.021_bib0013","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.06.021_bib0014","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.ejim.2023.06.021_bib0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.021_bib0016","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.39472","article-title":"Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a french nationwide study of ninety-two patients","volume":"68","author":"Crickx","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0017","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","article-title":"Treatment of systemic vasculitis with pooled intravenous immunoglobulin","volume":"337","author":"Jayne","year":"1991","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.ejim.2023.06.021_bib0018","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/rheumatology\/kez311","article-title":"The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis","volume":"59","author":"Shimizu","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2023.06.021_bib0019","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330807","article-title":"The american college of rheumatology 1990 criteria for the classification of wegener's granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.021_bib0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330806","article-title":"The american college of rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.021_bib0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0950-3579(97)80052-0","article-title":"Disease assessment and management of the vasculitides","volume":"11","author":"Luqmani","year":"1997","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0022","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/keq400","article-title":"A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2023.06.021_bib0023","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.021_bib0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the french vasculitis study group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2023.06.021_bib0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2023.06.021_bib0026","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2023.06.021_bib0027","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2215\/CJN.06250519","article-title":"Treatment of relapses in ANCA-associated vasculitis","volume":"14","author":"McClure","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0028","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11926-021-01010-0","article-title":"Novel Therapies for ANCA-associated Vasculitis.Curr","volume":"236","author":"Monti","year":"2021","journal-title":"Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.021_bib0029","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/jaut.1993.1018","article-title":"ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin","volume":"6","author":"Jayne","year":"1993","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ejim.2023.06.021_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2249.1994.tb06520.x","article-title":"Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin","volume":"95","author":"Pall","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0031","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2249.1991.tb05631.x","article-title":"Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis","volume":"83","author":"Rossi","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0033","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","article-title":"Modulation of the cellular immune system by intravenous immunoglobulin","volume":"29","author":"Tha-In","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ejim.2023.06.021_bib0034","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:39:30Z","timestamp":1760607570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523002169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":34,"alternative-id":["S0953620523002169"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.06.021","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}